文献速递心力衰竭与心肌病

门诊疑似新发心力衰竭:REVOLUTION HF研究

Suspected de novo heart failure in outpatient care: the REVOLUTION HF study.
PubMed 文献 · Eur Heart J · 2025-01-01

REVOLUTION HF研究基于瑞典两个医疗区域的门诊数据,纳入首次出现心衰体征或症状且NT-proBNP>300 ng/L的患者5942例,随访1年。结果显示疑似新发心衰患者全因死亡率和心衰住院率显著高于匹配对照,且事件率在就诊后数周内最高,医疗费用也更高。研究强调对疑似心衰患者需及时识别、评估和治疗。

要点

  • 门诊疑似新发心衰且NT-proBNP>300 ng/L的患者,1年内全因死亡率和心衰住院率显著高于对照。
  • 事件率在就诊后数周内最高,且随NT-proBNP水平升高而增加。
  • 此类患者医疗费用更高,主要由心衰和慢性肾脏病驱动。

核心结论

  • 疑似心衰且NT-proBNP升高的门诊患者,就诊后数周内死亡和患病风险高,医疗费用显著,需及时识别、评估和治疗。

研究设计与样本

  • 基于人群的REVOLUTION HF研究,覆盖瑞典两个大型医疗区域,纳入2015年1月1日至2020年12月31日首次就诊于门诊、记录有心衰体征(外周水肿)或症状(呼吸困难)且体征/症状出现±30天内NT-proBNP>300 ng/L的患者5942例,随访1年,并与无心衰史、无心衰体征/症状且NT-proBNP未升高的匹配对照(n=2048)比较。

主要发现

  • 疑似新发心衰患者中位年龄78.7岁,女性占54%;1年内29%获得心衰诊断。
  • 疑似新发心衰患者全因死亡率为11.7事件/100人年,匹配对照为6.5事件/100人年;心衰住院率为12.5事件/100人年 vs. 2.2事件/100人年。
  • 事件率在就诊后数周内最高,且随NT-proBNP水平升高而增加。
  • 部分患者已因其他适应症使用心衰指南指导的药物治疗,但新药启动情况不一。
  • 疑似新发心衰患者医疗费用高于匹配对照,主要由心衰和慢性肾脏病驱动。

临床怎么用

  • 对门诊出现心衰体征或症状的患者应检测利钠肽,NT-proBNP>300 ng/L提示疑似新发心衰需进一步评估。
  • 疑似新发心衰患者就诊后数周内事件风险最高,应尽快完成诊断评估并启动适当治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Ambulatory patients presenting with signs or symptoms of heart failure (HF) should undergo natriuretic peptide testing. Rates of death, HF hospitalization, and healthcare costs were examined in patients thus identified with suspected de novo HF. METHODS: This population-based study (REVOLUTION HF) encompassing two large healthcare regions in Sweden examined patients who presented to outpatient care for the first time between 1 January 2015 and 31 December 2020, who had a recorded sign (peripheral oedema) or symptom (dyspnoea) of HF, and whose N-terminal pro-B-type natriuretic peptide (NT-proBNP) measured >300 ng/L within ±30 days of that sign or symptom. Characteristics, outcomes, healthcare patterns, and healthcare costs for these patients were followed for 1 year. Comparisons were made with matched controls without history of HF, its signs, its symptoms, or elevated NT-proBNP. RESULTS: Overall, 5942 patients (median age 78.7 years; 54% women) presented with suspected de novo HF. Within 1 year, 29% had received a HF diagnosis. Patients with suspected de novo HF had higher rates of all-cause death (11.7 vs. 6.5 events/100 person-years) and HF hospitalizations (12.5 vs. 2.2 events/100 person-years) than matched controls (n = 2048), with the highest event rates in the weeks after presentation. Rates were higher with higher NT-proBNP levels. Although some patients already used HF guideline-directed medical therapies for other indications, initiation of new medications was variable. Healthcare costs were higher in patients with suspected de novo HF than in matched controls, driven mostly by HF and chronic kidney disease. CONCLUSIONS: Patients with suspected HF and elevated NT-proBNP had high mortality and morbidity in the weeks after presentation, and accrued substantial healthcare costs, highlighting an urgent need for prompt identification, evaluation, and treatment of HF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Anderson, Bayes-Genis, Bodegård, et al. Suspected de novo heart failure in outpatient care: the REVOLUTION HF study. Eur Heart J. 2025. PMID: 39935142. doi:10.1093/eurheartj/ehaf034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。